Poolbeg Pharma PLC POLB
LSE · Birleşik Krallık · Sağlık Teknolojisi
GBp 7,35-0,05 (-%0,68)
Piyasa kapalı· · GBp · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Piyasa kapalı· · GBp · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
Poolbeg Pharma PLC (AIM:POLB) CEO Jeremy Skillington spoke with Proactive's Stephen Gunnion about the company's interim results for the first half of 2026, progress with POLB 001 and the milestones investors can expect as its clinical development programme advances. Skillington said Poolbeg Pharma made "incredible progress" during the period, successfully transitioning POLB 001 from trial preparation into active clinical development. The programme is being studied in relapsed or refractory multiple myeloma patients, aiming to prevent cytokine release syndrome associated with cancer therapy. Th
Poolbeg Pharma PLC (AIM:POLB) CEO Jeremy Skillington spoke with Proactive's Stephen Gunnion after a positive interim safety review of its TOPICAL clinical trial targeting cytokine release syndrome (CRS) linked to cancer therapies. The review recommended the trial continue unchanged, with recruitment ongoing at leading UK sites and further sites being activated. Skillington said the latest data adds to the preclinical evidence, previous trial data and intellectual property supporting POLB 001, while Poolbeg continues discussions with potential pharmaceutical partners. He said the focus now is o
Galliford Try (LSE:GFRD) has secured places across all five regional lots of a £9.5 billion public sector construction framework covering schools, colleges, universities and healthcare buildings across Great Britain. The framework can run for up to eight years. Poolbeg Pharma (AIM:POLB) has received a Notice of Allowance from the Israeli Patent Office for its POLB 001 cytokine release syndrome patent, following earlier grants in Europe, Australia and Canada. The growing patent estate is expected to strengthen the drug's appeal to potential commercial partners. Tertiary Minerals (AIM:TYM) has r
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.